Advaxis Inc. announced on Tuesday that its final clinical data from Stage 1 of the ongoing two-stage Phase 2 study of axalimogene filolisba in patients with persistent or recurrent metastatic carcinoma of the cervix will be presented at the American Gynecological & Obstetrical Society's annual meeting.
Tom Hertzog, clinical director at the University of Cincinnati Cancer Institute, will present at the meeting in Half Moon Bay, California, on Sept. 17 at 11:15 a.m.
"There are limited therapies available in metastatic cervical cancer, particularly for patients who have failed at least one line of therapy," Hertzog said. "We see the potential for axalimogene filolisbac to fill a significant unmet need in the treatment of this disease and look forward to presenting these Stage 1 data at the AGOS annual meeting."
GOG-0265 is an open-label, single-arm, two-stage Phase 2 study designed to evaluate the safety, tolerability and efficacy of axalimogene filolisbac in around 67 patients with PRmCC who have received at least one prior line of systemic therapy.
The trial is being conducted in the U.S. by the Gynecologic Oncology Group under the sponsorship of the Cancer Therapy Evaluation Program of the National Cancer Institute.
Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology.